Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Version of Record online: 3 JUL 2012
© 2012 Wiley Periodicals, Inc.
Volume 35, Issue 12, pages 722–729, December 2012
How to Cite
Udell, J. A., Scirica, B. M., Braunwald, E., Raz, I., Gabriel Steg, Ph., Davidson, J., Hirshberg, B. and Bhatt, D. L. (2012), Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Clin Cardiol, 35: 722–729. doi: 10.1002/clc.22032
- Issue online: 7 DEC 2012
- Version of Record online: 3 JUL 2012
- Manuscript Revised: 16 MAY 2012
- Manuscript Received: 24 JAN 2012
Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis. In this review, we provide recommendations for the use of statins and aspirin for the prevention of cardiovascular events in high-risk patients with diabetes mellitus. Clin. Cardiol. 2012 doi: 10.1002/clc.22032
The SAVOR-TIMI 53 trial is sponsored by AstraZeneca and Bristol-Myers Squibb. Dr. Udell is a recipient of a Postdoctoral Research Fellowship from the Canadian Institutes for Health Research (CIHR) and Canadian Foundation for Women's Health. Dr. Scirica receives research grants from AstraZeneca, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer Healthcare, and Gilead Sciences and consultancy fees from Gilead Sciences, Lexicon, and Arena Pharmaceuticals. Dr. Braunwald receives research grants from AstraZeneca and Bristol-Myers Squibb. Dr. Raz has received honoraria/expenses for advisory board participation from AstraZeneca, Bristol-Myers Squibb, Novo Nordisk, Merck, Sharp & Dohme, and Eli Lilly; has served as a consultant for Andromea, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, HealOr, Insuline, Teva, and TransPharma; and has participated in speakers bureaus for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk, Johnson & Johnson, and Roche. Dr. Steg receives research grants from Servier. Dr. Davidson participated on advisory panels for AstraZeneca, Bristol-Myers Squibb, Merck, Johnson & Johnson, Boehringer Ingelheim, Eli Lilly, Generex Biotechnology, Novo Nordisk A/S, Roche Diagnostics, and Takeda Pharmaceutical Company and participated in speaker's bureaus for Eli Lilly and Takeda Pharmaceutical Company. Dr. Hirshberg is an employee of and holds stock in AstraZeneca. Dr. Bhatt discloses the following relationships—Advisory Board: Medscape Cardiology; Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers; Chair: American Heart Association Get With The Guidelines Science Subcommittee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees); Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda. The design and conduct of the SAVOR-TIMI 53 study are being done by the academic executive committee in collaboration with the sponsors.